Drug Trial Radar · NCT05745064
A Study of TL-925 as a Treatment for Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Feb 27, 2023
Primary completion
Jul 11, 2023
Study completion Jul 11, 2023
Sponsor
- Lead sponsor
- Telios Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.
Conditions
- Dry Eye Disease
Interventions
TL-925Drug
TL-925 is an eye drop.
PlaceboDrug
The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events during screening & treatment periodTime frame: Baseline to the end of day 29 (±2 days)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Aesthetic Eye Care
Newport Beach, California
Vision Institute
Colorado Springs, Colorado
Michael Washburn Center for Ophthalmic Research, LLC.
Indianapolis, Indiana
Andover Eye Associates
Andover, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.